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Background:KEAP1 is a ubiquitin ligase adaptor that promotes the ubiquitination anddegradation ofNRF2, a transcription
factor that drives the antioxidant response.
Results:Wilms tumor gene on the X chromosome (WTX) stabilizes NRF2 by competing with NRF2 for binding to KEAP1.
Conclusion:WTX regulates the antioxidant response.
Significance: This study reveals a novel regulatory mechanism governing the antioxidant response.
WTX is a tumor suppressor protein that is lost or mutated in
up to 30% of cases ofWilms tumor. Among its known functions,
WTX interacts with the -transducin repeat containing family
of ubiquitin ligase adaptors and promotes the ubiquitination
anddegradationof the transcription factor-catenin, a key con-
trol point in the WNT/-catenin signaling pathway. Here, we
report that WTX interacts with a second ubiquitin ligase adap-
tor, KEAP1, which functions to regulate the ubiquitination of
the transcription factor NRF2, a key control point in the antiox-
idant response. Surprisingly, we find that unlike its ability to
promote the ubiquitination of -catenin, WTX inhibits the
ubiquitination ofNRF2.WTXandNRF2 compete for binding to
KEAP1, and thus loss ofWTX leads to rapid ubiquitination and
degradation ofNRF2 and a reduced response to cytotoxic insult.
These results expand our understanding of themolecularmech-
anisms of WTX and reveal a novel regulatory mechanism gov-
erning the antioxidant response.
FAM123B/WTX/AMER1 (hereafter referred to as WTX) is
located on the X chromosome and encodes a tumor suppressor
protein that is lost ormutated in up to 30%of the cases ofWilms
tumor, the most common pediatric kidney cancer (1–3).
Recently, germ line mutations inWTX were also discovered in
families suffering from osteopathia striata congenital with cra-
nial sclerosis (OSCS),4 a debilitating skeletal dysplasia that is
often accompanied by developmental abnormalities and fatal-
ity in males (4, 5).
We previously reported that WTX regulates the stability of
-catenin (6). The regulation of the stability of -catenin is a
key control point of theWNT/-catenin signaling pathway and
the broader protein networks with which it interacts (7). In the
absence ofWNT ligand, -catenin is phosphorylated by a mul-
tiprotein complex often called the “destruction complex” and is
subsequently recognized by the SCFBTRC (Skp, Cullin, F-box)
ubiquitin ligase complex where it is ubiquitinated and targeted
for proteasomal degradation (8–10). In the presence of WNT
ligand, phosphorylation of -catenin is attenuated, resulting in
the nuclear accumulation of -catenin and the regulation of
transcription. Through proteomic and functional dissection of
the WNT/-catenin signaling pathway, we discovered that
WTX associates with -catenin as well as proteins in the
destruction complex, including adenomatous polyposis coli
(APC), AXIN1, BTRC (commonly referred to as -TrCP), and
FBXW11 (commonly referred to as-TrCP2) (6). Although the
precise mechanism(s) is unknown, WTX promotes the ubiq-
uitination and degradation of -catenin.
In addition to regulating the stability of -catenin, WTX has
also been shown to play a role in regulating WNT signal trans-
duction at the membrane (11). Furthermore, WTX controls
cell-cell adhesion through interactions with APC at the plasma
membrane (12) and modulates the activity of theWT1 (Wilms
tumor 1) transcription factor in the nucleus (13). Thus, it is
possible that the loss of WTX contributes to disease through
distinct mechanisms in specific subcellular compartments.
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Our previous analysis of the WTX protein interaction net-
work identified an association between WTX and KEAP1
(Kelch-like ECH-associated protein 1) (6). KEAP1 is a substrate
recognitionmodule for theCUL3-basedE3ubiquitin ligase that
constitutively ubiquitinates the transcription factor NRF2 (NF-
E2-related factor-2; NFE2L2) (14–16). In the presence of cyto-
toxic stress such as xenobiotics and antioxidants, KEAP1 is
inhibited, and NRF2 is no longer targeted for ubiquitination
and degradation. NRF2 then accumulates in the nucleus where
it regulates transcription of genes involved in the “phase II”
antioxidant response (17–19).
Although many studies have reported that small molecules
and stressors regulate NRF2 stability and function, relatively
little is known about regulation of KEAP1 and NRF2 through
protein-protein interactions. Here, we report that WTX
directly binds to KEAP1. Using gain-of-function and loss-of-
function approaches, we found that WTX stabilizes NRF2 and
positively regulates its transcriptional activity.We identified an
ETGEmotifwithin theKEAP1 interacting domain ofWTX that
is nearly identical to that of NRF2. We show that this motif is
not only required for the interaction ofWTXwithKEAP1 but is
also required for the ability of WTX to regulate NRF2 stability
and activity. Our observations support a model whereby WTX
competes withNRF2 for binding to KEAP1, thereby promoting
the NRF2-mediated antioxidant response.
EXPERIMENTAL PROCEDURES
Tissue Culture, Transfections, and Small Interfering RNAs—
All cell lines were grown in DMEM supplemented with 10%
fetal bovine serum in a 37 °C humidified incubator with 5%
CO2. Selection and passage of stable cell lines were performed
with 1.5 g/ml puromycin until cell death was no long appar-
ent. Expression constructs were transiently transfected in
HEK293T cells with Lipofectamine 2000 as directed by the
manufacturer (Invitrogen). Transient transfection of siRNA
was performed with Lipofectamine RNAiMAX, as directed by
the manufacturer (Invitrogen). Sequences of the siRNA sense
strands are as follows: WTX-A (CCU GGA GAU GAC UGC
CUU U dTdT), WTX-B (UAU GCC AGG GAG GCC CAC A
dTdT), NRF2 (GUAAGAAGCCAGAUGUUAA dTdT), and
KEAP1 (GGG CGU GGC UGU CCU CAA U dTdT). Control
siRNA was acquired from Ambion.
Plasmids and Expression Vectors—NRF2, WTX, KEAP1,
CUL3, and GFP cDNAs were created with standard PCR-based
cloning strategies. The reporter gene fusion construct for
human NQO1-ARE (hNQO1-ARE-luciferase) was a kind gift
from Jeffrey Johnson.
WTX Antibody Production—Amino acids 212–438 of WTX
were expressed as a GST fusion protein in Escherichia coli.
Purified GST-tagged WTX fragment was used as an immuno-
gen in rabbits, following established protocols by Cocalico Bio-
logicals, Inc. Prior to use in Western blot analysis or immuno-
staining, the antibody was affinity-purified over protein G
beads.
Affinity Pulldowns and Western Blotting—For streptavidin
affinity purification, cells were lysed in radioimmunoprecipita-
tion buffer (RIPA: 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 0.25% deoxycholic acid, 2 mM
EDTA) containing protease inhibitor mixture (Roche Applied
Science) and phosphatase inhibitormixture (Calbiochem). Cell
lysates were cleared by centrifugation and incubated with
streptavidin resin (Amersham Biosciences) before washing
with lysis buffer and eluting in NuPAGE loading buffer (Invit-
rogen). Detection of proteins by Western blot was performed
using the following antibodies: anti-NRF2 (H-300) polyclonal
(sc-13032, Santa Cruz Biotechnology), anti-KEAP1 polyclonal
(10503–2-AP, Proteintech), anti-HMOX1 monoclonal
(ab13248; Abcam), anti-FLAG M2 monoclonal (Sigma),
anti-HA polyclonal (1867423; Roche Applied Science), anti-
CTNNB1 polyclonal (9562; Cell Signaling Technology), anti-
GFP polyclonal (ab290, Abcam), and anti-TUBB1 monoclonal
(T7816; Sigma).
In Vitro Binding Experiments—HumanGST-VSV-WTXwas
purified fromE. coli andmixedwith purifiedCUL3orKEAP1 in
buffered 150mMNaCl. Following incubation for 30min at 4 °C,
complexes were washed with five bed volumes of 350 mM buff-
ered NaCl before elution and Western blot.
ARE-Luciferase Quantification—For DNA, HEK293T cells
were transfected with expression constructs, ARE-luciferase
(firefly), and a control plasmid containing Renilla luciferase
driven by a constitutive cytomegalovirus (CMV) promoter for
normalization. Approximately 6 h post-transfection, cells were
treated with 100 M tBHQ and incubated for an additional
12–16 h. Activation was measured as the ratio of firefly to
Renilla luciferase activity. For siRNA, HEK293T cells stably
expressing the ARE-luciferase and Renilla control reporters
were transfected with siRNA. Approximately 48 h later, 100M
tBHQ was added, and cells were incubated for an additional
16 h. Activation was then measured as described above.
NQO1-GFP Quantification—H1299 cells containing a YFP
fragment retrovirally inserted into intron 1 of the NQO1 gene
(170407PL1A2-NQO1) were a gift fromUri Alon and the Kahn
Protein Dynamics group. Ten thousand cells were seeded into
each well of a 96-well clear bottom white plate. Following an
18-h incubation period, cells were transfected with siRNA.
After an additional 24 h, 100 M tBHQ was added, and cells
were incubated for an additional 24 h. Cells were lysed in RIPA
buffer, and fluorescence at ex  485 nm was determined.
Cell Viability—HEK293T cells were transfected with siRNA
as described above in 6-well tissue-culture plates. Twenty hours
post-transfection, 30,000 cells were seeded into each well of a
96-well plate. Approximately 8 h later, cells were treated with
either DMSO (vehicle) or etoposide. The 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation
assay was performed 36 h post-treatment as described by the
manufacturer (ATCC, catalog no. 30-1010K-A).
RNA Isolation, Reverse Transcription, and Semi-quantitative
Real Time-PCR—Total RNA fromcellswas harvested inTRIzol
(Invitrogen) reagent according to the manufacturer’s instruc-
tions. RNA was quantified by UV spectrophotometry, and
cDNAwas created using the RevertAid First Strand cDNA syn-
thesis kit (Fermentas). PCR was performed in duplicate with
the LightCycler FastStart DNASYBRGreen kit (RocheApplied
Science) using the LightCycler 480 instrument (Roche Applied
Science). The PCR conditions are as follows: 35 cycles of ampli-
fication with 1 s denaturation at 95 °C and 5 s annealing at
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58 °C. A template free negative control was included in each
experiment. Quantitative light cycler PCR primers used are as
follows:WTX (GAC CCAAAAGGATGAAGC T and reverse
CCC CTC CAA AGA AAC TAG GC) and -actin (AGA GCA
AGA GAG GCA TCC TC and reverse CTC AAA CAT GAT
CTG GGT CA).
Cellular Extract Degradation—HEK293T cells were trans-
fected with eitherWTX-A or control siRNA. Forty eight hours
post-transfection, cells were resuspended in swelling buffer (20
mMHEPES, pH 7.7, 5mMMgCl2, 5mMKCl, 1mMDTT, 0.2mM
ATP, and protease inhibitor) at a ratio of 4:3. Resuspended pel-
lets were subjected to two rounds of freeze/thaw and passed
through a chilled 27-gauge needle two times. Lysates were then
centrifuged at 2,300  g for 5 min, and supernatant was trans-
ferred to a new tube and centrifuged for 30 min at 16,000  g.
The middle layer containing the cytosolic fraction was isolated
andused in subsequentNRF2degradation experiments. In vitro
transcription and translation of 35S-labeled NRF2 was per-
formed using the coupled transcription-translation T7 system
(Promega). Reactions consisted of 0.25 l of 35S-labeled NRF2,
15l of cell extract, and 1l of NRGmixture containing a 1:1:1
ratio of energy mix (150 mM creatine phosphate, 20 mMATP, 2
mM EGTA, and 20mMMgCl2), cycloheximide (0.1 g/ml), and
0.1 g/ml recombinant ubiquitin. One l of each reaction was
taken at 0, 30, 120, and 240 min and snap-frozen in loading
buffer. Samples were then run on a 3–12% gradient gel (Invit-
rogen), dried onto filter paper, and exposed to a phosphor
screen overnight. Bands were quantified, and percent of NRF2
remaining was determined as the ratio of each time point com-
pared with the zero time point.
InVitroUbiquitination—In vitro transcription/translation of
CUL3, NRF2, KEAP1, WTX, and GFP was performed with the
TNT Quick coupled Transcription/Translation System (Pro-
mega). Five l of each product was incubated in various com-
binations with recombinant ubiquitin (1.25 g), UBE1 (12.5
g), and UBCH5B (20 g) in the presence of 2 mM ATP, 5 mM
MgCl2. The mixtures were incubated at room temperature for
45 min. NRF2 was immunoprecipitated, and complexes were
analyzed by Western blot for ubiquitin.
Immobilized Metal Affinity Chromatography and Mass
Spectrometry—Affinity purification of GLUE-WTX and
FLAG-KEAP1 was performed as described previously (6). The
precipitated proteinswere trypsinized directly off beads follow-
ing reduction with 5 mM DTT and alkylation with 15 mM chlo-
roacetamide. Following “stage-tip” desalting (20), peptides
were resuspended in binding buffer (250 mM acetic acid and
30% acetonitrile) and incubated for 30 min with immobilized
metal affinity chromatography gel (I1408, Sigma). The phos-
phorylated peptides were washed three times with binding
buffer, eluted with 200 mM ammonium phosphate buffer, and
processed for mass spectrometry. Raw mass spectrometry data
were searched with SEQUEST (ThermoFisher), and phosphor-
ylation was queried via specification of a differential modifica-
tion of 79.6 atomic mass units on serine, threonine, or tyrosine.
Proteins were scored using the Institute for Systems Biology
trans-proteomic pipeline (21), and phosphosite accuracy was
evaluated using Ascore (22).
AlphaScreen—Recombinant GST-NRF2 and HIS6-hKELCH
were purified using standard techniques. Seventy ng of
AlphaScreen GSH-Donor and AlphaLISA nickel-acceptor
beads (PerkinElmer Life Sciences) were mixed with 100 nM
HIS6-hKELCH, 20 nM GST-NRF2, and respective peptides in
binding buffer containing 20 mM Tris, pH 8, 200 mM NaCl, 1
mM DTT, and 0.05% Tween 20. Reactions were incubated at
room temperature for 30 min, and AlphaScreen Signal was
determined with an Envision plate-reader (PerkinElmer Life
Sciences). Peptide sequences are as follows: NRF2 16-mer,
AFFAQLQLDEETGEFL; WTX 16-mer, ASSLEEPHSPET-
GEKV; and -catenin 26-mer, KAAVSHWQQQSYLDSGIH-
SGATTTAP.
Statistical Analysis—Student’s t test was used to assess the
statistical significance of the differences between the different
groups; a p value of 0.05 was considered significant.
RESULTS
WTX Directly Interacts with KEAP1—The WTX gene
encodes an 1135-amino acid protein (WTX-WT) characterized
by multiple protein-protein interaction domains and an N-ter-
minal phosphatidylinositol 4,5-bisphosphate binding domain
that mediates its localization to the plasma membrane (12).
Through in-frame alternative splicing, a shorter isoform
(WTX-S) of 858 amino acids is produced that lacks residues
50–326 and does not localize to the plasma membrane (13).
Here, we employ an 804-amino acid variant ofWTX, previously
reported by us and by Grohmann et al. (12) that shares perfect
identity with WTX-WT through residue 785. This isoform
contains theN-terminal phosphatidylinositol 4,5-bisphosphate
binding domain, as well as the binding domains for KEAP1,
-catenin, APC, AXIN1, BTRC, and FBXW11.
We previously observed that KEAP1 co-purifies with WTX
protein complexes (6) as determined by mass spectrometry-
based proteomics. To validate this interaction, we engineered
HEK293T cells to express a fusion protein containing anN-ter-
minal streptavidin-binding protein, calmodulin-binding pro-
tein, the hemagglutinin epitope (HA), and WTX (GLUE-
WTX). Affinity purification of GLUE-WTX and Western
blotting confirmed that endogenous KEAP1 forms a complex
with GLUE-WTX (Fig. 1A, compare lane 10 with control lane
7). This interactionwas independent of the activity of either the
KEAP1/NRF2 or the WNT/-catenin signaling pathways as
neither the KEAP1 antagonist tBHQ (tert-butylhydroquinone)
nor WNT3A conditioned media affected the interaction of
WTX with KEAP1 (Fig. 1A, compare lanes 10, 11, and 12).
To determine whether WTX directly interacts with KEAP1,
we tested whether recombinant GST-WTX was able to pull
down recombinant KEAP1 in vitro. Using this method, we
determined that WTX directly interacts with KEAP1 but not
with the KEAP1-associated CUL3 protein (Fig. 1B, compare
lanes 4 and 5). Together with our previous work (6), these data
demonstrate thatWTXdirectly binds the substrate recognition
modules of two different E3 ubiquitin ligases, namely BTRC
and KEAP1.
KEAP1 has three well defined domains, an N-terminal BTB
domain that binds CUL3 (14), an intervening region, and the
C-terminal KELCH repeats that form a -propeller fold that
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binds NRF2 (23). To determine the domain in KEAP1 that
binds WTX, HEK293T cells expressing GLUE-WTX were
transfected with FLAG-KEAP1, FLAG-BTB, or FLAG-KELCH
constructs. Affinity purification of GLUE-WTX revealed an
associationwith full-length KEAP1 and the KELCH repeats but
not with the KEAP1 BTB domain (Fig. 1C, compare lanes 6, 7,
and 8). Taken together, our data suggest that WTX directly
associates with the KELCH repeats of KEAP1. Despite its asso-
ciation with the substrate-recognition domain of KEAP1, the
steady-state levels ofWTX are not regulated by KEAP1 or pro-
teasome-mediated degradation (supplemental Fig. S1). Thus
we conclude that WTX is not a substrate of KEAP1.
WTX Promotes NRF2-dependent Transcription—Based on
the physical interaction between WTX and KEAP1, we next
tested if WTX regulates NRF2 activity. First, we employed a
luciferase reporter containing the ARE of NQO1, an NRF2 tar-
get gene (24). Two nonoverlapping WTX-specific siRNAs
decreased both basal and tBHQ-induced activation of this
ARE-luciferase reporter in HEK293T cells, similar to the effect
of depleting NRF2 with siRNA (Fig. 2, A and B). Conversely,
overexpression of WTX activated the luciferase reporter com-
pared with control GFP (Fig. 2C). Second, because the engi-
neered luciferase reporter may not accurately represent endog-
enous transcription, we tested whether WTX regulates the
expression of endogenous NQO1. We utilized the H1299 non-
small cell lung cancer cell line containing a YFP fragment ret-
rovirally inserted into intron 1 of the endogenous NQO1
genomic locus resulting in an NQO1-YFP product (25). Induc-
tion of YFP in the presence of tBHQ was significantly lower in
cells transfected withWTX siRNA compared with control (Fig.
2D). Taken together, these observations suggest that WTX is a
positive regulator of NRF2-dependent transcription, unlike its
role as a negative regulator of -catenin-dependent transcrip-
tion (6).
FIGURE 1. WTX directly interacts with KEAP1. A, GLUE-WTX interacts with endogenous KEAP1. HEK293T parental or HEK293T cells stably expressing GLUE-
WTX were treated with DMSO, 100 M tBHQ, or 100 M tBHQ and WNT3A conditioned media (WNT3ACM) for 2 h. Lysates were subjected to streptavidin affinity
pulldown (AP) followed by Western blot (WB) analysis. B, WTX directly binds KEAP1. Recombinant GST-VSV-WTX was incubated with recombinant CUL3 or
KEAP1. After GST affinity purification, complexes were washed, and associated proteins were resolved by Western blot. * denotes full-length GST-VSV-WTX.
C, WTX interacts with the KELCH repeats of KEAP1. HEK293T cells stably expressing GLUE-WTX were transfected with FLAG-tagged KEAP1 constructs. Lysates
were subjected to streptavidin affinity pulldown followed by Western blot analysis. IB, immunoblot.
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KEAP1 and NRF2 are known to play opposing roles in the
cellular response to oxidative stress and chemotherapeutics,
most notably in non-small cell lung cancer where constitutive
activation of NRF2 promotes resistance to chemotherapeutics
(26). To determine whetherWTX plays a similar role, we asked
if loss ofWTX sensitizes cells to the chemotherapeutic reagent
etoposide. Compared with control, cells transfected with
siRNA targeting WTX were more sensitive to cell death in the
presence of etoposide as determined by mitochondrial activity
(Fig. 2E). We conclude from these experiments that WTX and
NRF2 promote resistance to apoptotic inducing reagents.
WTX Regulates the Steady-state Levels of NRF2 by Inhibiting
Its Ubiquitination—As WTX regulates the stability of
-catenin (6), we hypothesized that WTX also regulates the
stability of NRF2. To test this, we transfected HEK293T cells
with control, NRF2, orWTX siRNAs and monitored the levels
of NRF2 and its target HMOX1 following treatment with
tBHQ. siRNA-mediated silencing of WTX in HEK293T cells
resulted in lower NRF2 and HMOX1 protein levels compared
with control (Fig. 3A, compare lanes 3 and 4 with control lane
1). Similar results were also observed in cell lines derived from
normal lung (BEAS2B) and lung carcinoma (A549) (Fig. 3B,
compare lane 3with control lane 1 and lane 6with control lane
4). Of note, whereas HEK293T and BEAS2B cells have wild-
type KEAP1, A549 cells harbor a G333C mutation in the
KELCH repeats of KEAP1 that partially impairs the ubiquitina-
tion of NRF2, resulting in relatively high basal levels of NRF2.
As a complement to the siRNA-based loss-of-function
approach, we tested whether overexpression ofWTX results in
increased levels of NRF2 protein. In HEK293T cells transiently
transfected with a VENUS-WTX expression construct, we
observed increased levels of endogenous NRF2 (Fig. 3C, com-
pare lane 4with control lane 2, and lane 5with control lane 3).
Combined, these results suggest that WTX regulates the
steady-state levels of NRF2.
We next asked if WTX regulates the steady-state levels of
NRF2 by inhibiting the degradation of NRF2 protein. To test
this, we measured the degradation of NRF2 in cell-free extracts
generated fromHEK293T cells. 35S-Labeled NRF2 was less sta-
ble in extracts purified from cells transfected withWTX siRNA
compared with control extracts (Fig. 3D). Conversely, when
extracts from HEK293T cells were supplemented with recom-
binant WTX, levels of 35S-labeled NRF2 were relatively stable
compared with control, suggesting that WTX inhibits the deg-
radation of NRF2 (Fig. 3E). Of note, although we observed that
the half-life of exogenousNRF2 in cell extracts is6 h, previous
reports have demonstrated that exogenous and endogenous
NRF2 has a half-life of 20 min in intact cells (15, 27). We also
observed that NRF2 has a half-life of minutes in intact cells
FIGURE 2. WTX promotes NRF2-dependent transcription. A, two nonoverlapping siRNAs reduce WTX transcript levels. HEK293T cells were transfected with
the indicated siRNAs. Total RNA was isolated 48 h after transfection, and relative transcript levels were quantified as the ratio compared with -actin transcripts.
B, WTX is required for activation of an ARE-luciferase reporter. HEK293T cells stably expressing an ARE-driven firefly-luciferase reporter as well as a control
CMV-driven Renilla luciferase reporter were transfected with siRNAs and either DMSO or tBHQ. Relative levels of ARE-driven firefly luciferase compared with
control CMV-driven Renilla luciferase are plotted. Error bars represent means  S.D. of three technical replicates. Data are representative of three biological
replicates. C, overexpression of WTX activates an ARE-luciferase reporter. HEK293T cells were transfected with the ARE-firefly luciferase reporter, a control CMV
Renilla luciferase control reporter, and the indicated FLAG-tagged DNA constructs. Cells were treated with tBHQ, and luciferase levels were quantified as in B.
D, loss of WTX inhibits transcription of endogenous NQO1. H1299 cells expressing an NQO1-YFP fusion protein under control of the endogenous promoter were
transfected with the indicated siRNAs and treated with either DMSO or tBHQ. Relative YFP fluorescence is plotted. Error bars represent means  S.D. of four
technical replicates. Data are representative of three biological replicates. *, p  0.02 when comparing WTX siRNA with control. E, loss of WTX increases the
cellular sensitivity to etoposide. HEK293T cells were transfected with the indicated siRNAs and treated with etoposide. Cell viability was determined by
measuring the metabolic activity of mitochondria (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay). *, p  0.03 when comparing
NRF2 and WTX siRNAs with control.
WTX/FAM123B Regulates NRF2 Protein Stability
FEBRUARY 24, 2012 • VOLUME 287 • NUMBER 9 JOURNAL OF BIOLOGICAL CHEMISTRY 6543
(supplemental Fig. S1B), and we attribute the differences in
extracts to differences in experimental systems.
As WTX directly binds to KEAP1 and inhibits the degrada-
tion of NRF2, we hypothesized thatWTX inhibits the ubiquiti-
nation of NRF2 by KEAP1. To test this hypothesis, we utilized
an in vitro assay tomonitor the ubiquitination of NRF2. In vitro
transcribed/translated CUL3, KEAP1, and NRF2 were com-
bined with either mock, GFP, or WTX and incubated with
ubiquitination reagents. NRF2 was then immunoprecipitated,
and ubiquitination was monitored byWestern blot. Compared
with control, WTX inhibited the ubiquitination of NRF2 (Fig.
3F, compare lane 3 with control lane 1). Taken together, these
results indicate that WTX stabilizes NRF2 by inhibiting
KEAP1-dependent ubiquitination.
FIGURE 3. WTX regulates the steady-state levels of NRF2 by inhibiting its ubiquitination. A and B, knockdown of WTX inhibits stabilization of NRF2. A,
HEK293T cells were transfected with the indicated siRNAs and treated with tBHQ (100 M, 4 h) preceding lysis and Western blot (WB) analysis. B, BEAS2B and
A549 cell lines were transfected with the indicated siRNAs. BEAS2B cells were treated with tBHQ preceding lysis and Western blot analysis. C, overexpression
of WTX stabilizes NRF2. HEK293T cells were transfected with the indicated constructs and analyzed as in A and B. D and E, WTX regulates NRF2 steady-state
levels. D, HEK293T cells were transfected with the indicated siRNAs and cellular extracts were purified. 35S-Radiolabeled NRF2 was added to cellular extracts,
and degradation was monitored over time by autoradiography. A representative autoradiograph and quantification from three independent experiments is
shown. E, 35S-NRF2 and recombinant GST or GST-WTX were added to HEK293T cellular extracts. 35S-NRF2 degradation was monitored and quantified as in E. F,
in vitro transcribed and translated CUL3, NRF2, KEAP1, WTX, and GFP were mixed as indicated. NRF2 was immunoprecipitated (IP) from each reaction, and
ubiquitination was observed by Western blot analysis.
WTX/FAM123B Regulates NRF2 Protein Stability
6544 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 9 • FEBRUARY 24, 2012
WTX Interacts with KEAP1 through an ETGEMotif—KEAP1
and members of the BTRC family (BTRC and FBXW11) are
substrate-adaptor proteins that bind to CUL3- and CUL1-
based E3 ubiquitin ligase complexes, respectively (9, 16). To
gain insight into the mechanism(s) by which WTX regulates
these complexes, we wanted to define the domain(s) within
WTX that bind KEAP1 and the BTRC family (BTRC and
FBXW11). Numerous fragments of the WTX protein were
expressed as VENUS fusions in HEK293T cells engineered to
express GLUE-KEAP1 or GLUE-FBXW11. Interestingly, affin-
ity purification and Western blot revealed that WTX binds
KEAP1 and FBXW11 through separable domains.Weobserved
that WTX fragments containing amino acids 1–367 and 212–
438 interacted with KEAP1 suggesting that amino acids 212–
367 are required to bindKEAP1, whereas amino acids 439–624
are required to bind FBXW11 (Fig. 4, A and B, respectively;
results are summarized in Fig. 4C).
Within the KEAP1 binding domain of WTX, our attention
was drawn to amino acids 286–291, containing the sequence
SPETGE (Fig. 4C). KEAP1 directly interacts with a conserved
DXETGE motif within NRF2 (28), raising the possibility that
WTX binds KEAP1 through its ETGE motif. To test this, we
expressed a WTX construct lacking amino acids 288–291
(VENUS-WTX ETGE) in GLUE-KEAP1 cells. Western blot
analysis of KEAP1 affinity-purified complexes revealed sub-
stantially less WTX ETGE compared with wild-type WTX
(Fig. 4D, compare lanes 2 and 3). Threonine 80 within the
ETGEmotif of NRF2makes critical contacts with KEAP1 and is
FIGURE 4. WTX interacts with KEAP1 through an ETGE motif. A and B, WTX associates with KEAP1 and FBXW11 through separable domains. A, HEK293T cells
stably expressing GLUE-KEAP1 were transfected with the indicated VENUS-WTX deletion constructs. Lysates were subjected to streptavidin affinity pulldown
(AP) followed by Western blot (WB) analysis. B, HEK293T cells stably expressing GLUE-FBXW11 were transfected with the indicated VENUS-WTX deletion
constructs. Lysates were analyzed as in B. C, schematic representation of the observed interactions in Fig. 5, A and B. Below the schematic, conserved residues
of WTX are indicated by gray shading. Conserved residues that are identical to the NRF2 degron are indicated by red shading. D, interaction between WTX and
KEAP1 is mediated through an ETGE motif. The indicated VENUS-WTX mutation constructs were transfected into GLUE-KEAP1 cells. Complexes were purified
and analyzed as in A and B.
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required for interacting with KEAP1 (29). Similarly, we
observed thatmutation of threonine 289 to alanine in the ETGE
motif of WTX disrupts the interaction with KEAP1 (Fig. 4D,
compare lanes 2 and 4). Interestingly, lysine 292, adjacent to the
ETGE motif, is mutated to asparagine in several reported
Wilms tumor cases and a single instance of acute myeloid leu-
kemia (1, 3, 30). Comparedwithwild-typeWTX, KEAP1 pulled
down less WTX K292N, although more than WTX ETGE
(Fig. 4D, compare lanes 2, 3, and 5). Combined, these results
suggest that WTX binds to KEAP1 through a similar motif as
NRF2.
One notable difference between the KEAP1 interaction
domains of NRF2 andWTX is the two amino acids upstream of
their respective ETGEmotifs. The humanNRF2motif contains
a conserved aspartic acid that interacts with two water mole-
cules that in turn hydrogen bond with two arginine residues in
KEAP1 (29). In place of the aspartic acid, WTX contains a ser-
ine (residue 286). Interestingly, mutation of serine 286 to ala-
nine inhibited the ability of KEAP1 to pull downWTX (Fig. 4D,
compare lanes 2 and 6). Based on the crystal structure of the
KELCH repeats and anNRF2 peptide (23, 29), we reasoned that
mutation of serine 286 to an acidic residue would enhance the
interaction between WTX and KEAP1. Although we only
observed a modest increase in the interaction between KEAP1
andWTX S286E, WTX S286D was significantly enriched rela-
tive to wild-type WTX in KEAP1 pulldowns (Fig. 4D, compare
lanes 2, 7, and 8). We conclude from these experiments that in
addition to the ETGE motif, serine 286 is also important in the
KEAP1 interacting domain of WTX.
Serine 286 Is Phosphorylated inVivo—Given thatmutation of
serine 286 to alanine and aspartic acid differentially affected the
ability of KEAP1 to pull down WTX, we hypothesized that
phosphorylation of WTX could affect its interaction with
KEAP1. To directly test whether WTX is phosphorylated in
vivo, we trypsinized GLUE-WTX complexes from HEK293T
cells and enriched for phosphorylated peptide fragments by
immobilized metal affinity chromatography. Peptides were
then analyzed for the presence of phosphorylation by mass
spectrometry.We identified 16 unique phosphorylation sites in
16 unique mono- or di-phosphorylated peptides (Table 1 and
supplemental Fig. S2). Of the 16 unique peptides, two were
phosphorylated at serine 286, including one with a second
phosphorylated site at serine 280. The phosphorylation at ser-
ine 286 is considered definitive by the Ascore phosphorylation
site algorithm, where any score above 19 has a greater than 99%
chance of certainty (22).
Finally, we wanted to determine whether endogenous WTX
is phosphorylated on serine 286 when associated with KEAP1.
Immobilized metal affinity chromatography-enriched phos-
phopeptides from FLAG-KEAP1 affinity-purified protein com-
plexes were identified by mass spectrometry. Within FLAG-
KEAP1 complexes, we identified six phosphorylation sites on
endogenous WTX, including serine 286 (Table 2 and supple-
mental Fig. S3). Although these data do not rule out the possi-
bility that unphosphorylatedWTX interacts with KEAP1, they
confirm that endogenousWTX is phosphorylated at serine 286
and interacts with KEAP1.
WTX Competes with NRF2 for Binding to KEAP1—Our
observation that WTX interacts with KEAP1 through a similar
motif as NRF2 raises the possibility that WTX and NRF2 com-
pete for the samebinding site inKEAP1.Todirectly test this, we
utilized an AlphaScreen approach to ask if aWTX peptide con-
taining the SPETGE sequence could inhibit the interaction
between NRF2 and KEAP1. We observed a strong interaction
between GST-NRF2 and HIS6-hKELCH (KELCH repeats of
KEAP1 that directly interact with NRF2) as indicated by a
robust AlphaScreen signal. The specificity of the interaction
was validated as a peptide containing the DXETGE motif of
NRF2 inhibited the AlphaScreen signal in a dose-dependent
manner (Fig. 5A). Whereas a control -catenin peptide had no
effect, a peptide containing the SPETGE motif of WTX (WTX
16-mer) inhibited the interaction between NRF2 and the
KELCH repeats of KEAP1 in a dose-dependent manner (Fig.
5A). These results suggest that WTX and NRF2 compete for
binding to KEAP1.
If WTX regulates NRF2 steady-state levels through direct
competition with KEAP1, we would expect that mutations in
WTX that inhibit its interaction with KEAP1 should impair its
ability to regulate the steady-state levels of NRF2. To test this,
we assessed the ability of VENUS-WTX ETGE to stabilize
TABLE 1
Phosphorylated WTX peptides identified by mass spectrometry
Asterisk indicates phosphorylated residue. NAmeans not applicable. The particular peptides in this table that are important for our overall findings are shown in boldface
type.
Unique peptide sequence Peptide probability Index Ascore1 Ascore2
KENANPQDAPGPKVS*PTPEPSPPATEK 0.99 240 32.48 NA
VSPT*PEPSPPATEK 0.99 242 6.46 NA
VSPTPEPS*PPATEK 0.99 246 33.57 NA
KENANPQDAPGPKVS*PTPEPS*PPATEK 0.99 240, 246 32.48 33.57
VSPT*PEPS*PPATEK 0.99 242, 246 6.46 33.57
PAPEASS*LEEPHSPETGEK 0.89 280 9.7 NA
PAPEASSLEEPHS*PETGEK 0.99 286 46.85 NA
PAPEASS*LEEPHS*PETGEK 0.91 280, 286 9.7 46.85
T*SLKSFDSLTGCGDIIAEQDMDSMTDSMASGGQR 0.99 317 0 NA
FDS*LT*GCGDIIAEQDMDSMTDSMASGGQR 0.29 324, 326 11.63 12.28
PNMNLGYHPTT*SPGHHGYMLLDPVR 0.99 429 0 NA
PNMNLGYHPTTS*PGHHGY 0.57 430 0 NA
DSYSGDALYEFYEPDDSLENS*PPGDDCLY*DLH 0.85 518, 526 0 0
SSEMFDPFLNFEPFLSS*RPPGAMET*EEE 0.80 548, 556 2.99 5.45
ITS*AFPTTASSEPDWR 0.21 683 0 NA
RQVTQACGT*W 0.99 803a 69.97 NA
a Threonine 803 is absent in the full-length isoform of WTX(1–1135).
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NRF2.Whereas overexpression ofwild-typeWTXrobustly sta-
bilized NRF2 in a dose-dependent manner, WTX ETGE only
modestly stabilized NRF2 at significantly higher levels of
expression (Fig. 5B, compare lane 4 with lanes 6 and 7). In
addition to regulating the steady-state levels of NRF2, the inter-
action ofWTXwith KEAP1 should also regulate NRF2-depen-
dent transcription. To test this, we examined whether the var-
ious WTX mutants could regulate NRF2-dependent
transcription in the presence of exogenous KEAP1. Overex-
pression of FLAG-NRF2 activated an ARE-luciferase reporter
and was partially inhibited by overexpression of KEAP1. Con-
comitant expression of the various WTX mutants rescued
FLAG-NRF2 activity correlating with the ability of the WTX
mutants to bind KEAP1 (Fig. 5C). We conclude from these
experiments that the ability ofWTX to regulate the steady-state
levels of NRF2 andNRF2-dependent transcription directly cor-
relates with its ability to bind KEAP1. Taken together, our data
suggest that WTX regulates NRF2 steady-state levels and
NRF2-dependent transcription by competing for binding to
KEAP1.
TABLE 2
Phosphorylated WTX peptides associated with KEAP1
Asterisk indicates phosphorylated residue. NAmeans not applicable. The particular peptides in this table that are important for our overall findings are shown in boldface
type.
Unique peptide sequence Peptide probability Index Ascore1 Ascore2
KENANPQDAPGPKVS*PTPEPS*PPATEK 0.81 240, 246 1 7.23
VSPT*PEPS*PPATEK 0.99 242, 246 13.7 38.5
VSPTPEPS*PPATEK 0.99 246 20.22 NA
PAPEASSLEEPHS*PETGEK 0.99 286 7.79 NA
AYPTYS*PPEDPEEEEVEK 0.99 749 19.85 NA
FYQGLPWGVSS*LPR 0.99 868 7.53 NA
FIGURE 5. WTX competes with NRF2 for binding to KEAP1. A, WTX peptide containing the ETGE motif inhibits the interaction between KEAP1 and NRF2. A
fixed concentration of GST-NRF2 and HIS6-hKELCH was mixed with increasing amounts of the indicated peptides in the presence of GSH donor and nickel
acceptor AlphaScreen beads. The interaction between GST-NRF2 and HIS6-hKELCH is represented as AlphaScreen signal. Error bars represent means  S.D. of
three technical replicates. Data are representative of three biological replicates. B, ETGE motif is required to stabilize NRF2. HEK293T cells were transfected with
the indicated expression constructs. Proteins were analyzed by Western blot (WB). C, ETGE motif is required to regulate NRF2 transcriptional activity. HEK293T
cells in a 48-well tissue culture plate were transfected with 5 ng of an ARE-luciferase reporter, 10 ng of a control CMV Renilla luciferase control reporter, and the
indicated DNA (2 ng of FLAG-NRF2, 10 ng of GLUE-KEAP1, and 10 ng of VENUS constructs). The relative levels of ARE-driven firefly luciferase compared with
control CMV-driven Renilla luciferase are plotted. Error bars represent the means  S.D. for three replicates. Data are representative of three independent
experiments. Lysates were also analyzed by Western blot analysis for relative WTX and KEAP1 expression.
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DISCUSSION
The WTX gene encodes a tumor suppressor protein; it is
located on the X chromosome and is somatically lost or
mutated in 7–30% of cases of Wilms tumor (1–3). Germ line
mutations in WTX give rise to OSCS, a debilitating and fatal
disease that largely affects the skeletal system (4, 5). As the
discovery of WTX and its mutations in human disease is rela-
tively new, the molecular function(s) and developmental or
homeostatic consequences of its loss is only beginning to be
unraveled. Compelling data from numerous research groups
have described functions for WTX in controlling WNT/-
catenin signaling, cell-cell adhesion, apoptosis, and transcrip-
tion (1, 6, 11–13). Recently, characterization ofWtx deletion in
mice revealed that Wtx regulates mesenchymal progenitor cell
fate specification in part through -catenin (31).
Here, we expand on the knowledge of the molecular mecha-
nisms of action of WTX with the observation that WTX regu-
lates the steady-state levels ofNRF2 andNRF2-dependent tran-
scription by competing with NRF2 for binding to KEAP1.
KEAP1 forms a homodimer and interacts with CUL3 through
its BTBdomain (32, 33) and interactswith theN-terminalNeh2
domain of a single NRF2 molecule through its KELCH repeats.
The Neh2 domain of NRF2 contains two highly conserved
regions, one bearing anLXXQDXDLG (DLG)motif (34, 35) and
the other bearing a DXETGE motif (28). These motifs interact
with a separate KEAP1 molecule in the KEAP1 homodimer,
although the DXETGE motif binds with 100-fold higher
affinity (36). WTX contains a similar SPETGE motif that can
directly inhibit the interaction between NRF2 and the KELCH
repeats of KEAP1 in vitro. As WTX does not contain a DLG
motif similar to NRF2, it is possible that NRF2 can still interact
with a KEAP1 dimer through this low affinity interactionmotif.
We hypothesize that WTX enhances NRF2 steady-state levels
by disrupting the conformation of the E3 ubiquitin ligase com-
plex, resulting in lower ubiquitination of NRF2. In support of
our findings, expression of the NRF2 target genes NQO1 and
HMOX1 was significantly enhanced in HEK293T cells overex-
pressing a fragment ofWTX containing the KEAP1 interaction
domain (37).
In addition to the ETGEmotif, we determined that serine 286
is also required for the ability of WTX to interact with KEAP1
and regulate NRF2. Interestingly, mutation of serine 286 to
either glutamic or aspartic acid enhanced the functional effects
of WTX. Although these mutations may only present confor-
mational changes inWTX that make it more suitable for bind-
ing to KEAP1, both glutamic and aspartic acid resemble phos-
phorylated serine. Thus, phosphorylation ofWTX at serine 286
may increase its affinity forKEAP1. Furthermore,we found that
WTX is phosphorylated in vivo, and KEAP1 interacts with
endogenous WTX that is phosphorylated at serine 286, raising
the intriguing possibility that the interaction between WTX
and KEAP1 is regulated by a yet to be identified kinase(s).
Under normal conditions, NRF2 is constitutively ubiquiti-
nated through its association with KEAP1 (14–16). In the pres-
ence of oxidative stress, cysteine residues in KEAP1 are modi-
fied resulting in a conformational change that disrupts the
ubiquitination of NRF2, and NRF2 accumulates in the nucleus
where it regulates gene transcription (16, 38). In addition to our
findings, several recent studies have also revealed that NRF2
signaling is regulated through protein-protein interactions.
The cyclin-dependent kinase inhibitor p21, a p53-regulated
gene with pro-survival properties, was recently shown to bind
the DLGmotif of NRF2 and inhibit its interaction with KEAP1,
resulting in elevated NRF2 levels under both basal and chemi-
cally induced conditions (39). Another recent study identified
p62 as a novel interactor of KEAP1 (40). During autophagy, p62
directs ubiquitinated proteins to degradation by the lysosome.
By binding to KEAP1 through an ETGE-like motif similar to
that of NRF2 and WTX, p62 targets KEAP1 for autophagic
degradation, thus contributing to the stabilization of NRF2.
Combined with WTX, these examples highlight the complex
regulation of NRF2 degradation and its importance in both
homeostasis and response to cytotoxic stress.
Whereas WTX inhibits the ubiquitination of NRF2, we pre-
viously reported that WTX promotes the ubiquitination of
-catenin by the SCFBTRC ubiquitin ligase complex. To our
knowledge, WTX is the first described protein to interact with
two E3 ubiquitin ligase adaptors and have opposite regulatory
effects on their respective substrates. How is this possible?
WTX interacts with the KELCH repeats that form the -pro-
peller fold of KEAP1 and likely inhibits the formation of a func-
tional CUL3-KEAP1-NRF2 complex. Through a separable
domain, WTX interacts with both BTRC and -catenin, sug-
gesting that it binds to an intact SCFBTRC-substrate complex
(6). BTRC also employs a -propeller fold for substrate capture
(41), but it is unlikely that WTX interacts with the -propeller
fold of BTRC in a similar fashion as KEAP1 as this would inhibit
the formation of a functional CUL1-SKP1-BTRC--catenin
complex and result in elevated -catenin levels. Interestingly, a
recent study demonstrated that NRF2 is phosphorylated by
GSK3 in the central Neh6 domain (DSGIS, residues 334–
338), creating an SCFBTRC destruction motif similar to that of
-catenin (42). This phosphorylated form of NRF2 is recog-
nized by BTRC. Additionally, KEAP1 and BTRC have been
identified in the same complex bymass spectrometry (43). This
raises the possibility that multiple E3 ubiquitin ligase com-
plexes consisting of a KEAP1 homodimer, a BTRChomodimer,
or a KEAP1/BTRC heterodimer regulate the ubiquitination of
NRF2. AsWTX interacts with BTRC and KEAP1 through sep-
arable domains, we hypothesize that WTX coordinates the
adaptors in the E3 ubiquitin ligase complexes, resulting in vari-
able ubiquitination of substrates.
Although most commonly lost through gene-encompassing
deletions, a small percentage of WTX mutations identified in
Wilms tumor yield single amino acid substitutions and trun-
cated proteins. Conversely, the majority of WTX mutations
identified in OSCS yield truncated proteins. Aligning the loca-
tion of these mutations with the WTX protein interaction
domains suggests relationships of these diseases with specific
binding interfaces. The KEAP1 interaction domain lies N-ter-
minal to the domains that bind -catenin/BTRC/APC and
WT1 and remains intact in 9 out of the 20 reported mutation
products. Of note, we determined that the K292N substitution
inhibited the association of WTX and KEAP1. The -catenin/
BTRC/APC interacting domains encompass residues 280–
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839. Of the 20 reported mutations, 11 are predicted to alter
these binding activities. As the C terminus ofWTXbindsWT1,
this interaction is lost in all truncation products derived from
mutations in WTX. These correlations suggest that whereas
WT1 is likely central to WTX-associated diseases, the WTX-
KEAP1 and WTX--catenin/BTRC/APC functional relation-
ships may contribute to a subset of Wilms tumor and OSCS,
perhaps accounting for variability in disease onset or
progression.
The observation that WTX regulates the NRF2-mediated
antioxidant response supports further study of its role in dis-
ease beyond Wilms tumor and OSCS. One of the best-studied
diseases with altered KEAP1/NRF2 activity is non-small cell
lung cancer, where mutations in KEAP1 lead to constitutive
NRF2-mediated transcription. Consequently, cultured lung
cancer cell lines with constitutive NRF2 activity are resistant to
cell death induced by etoposide (26). Similarly, silencing NRF2
restores resistance to chemotherapeutics in KEAP1 mutant
cells (44).We find that silencingWTX sensitizesHEK293T cells
to death induced by etoposide, similar to loss of NRF2. Inter-
estingly, although WTX expression is diminished in adult
mouse brain and kidney compared with embryonic tissues,
expression levels remain high in the lung, suggesting it may
contribute to lung cell homeostasis in the adult (1). Coupled
with the established roles ofWTX inWilms tumor andKEAP1/
NRF2 in lung cancer, our data support future investigations
into a functional role for WTX in lung cancer and other dis-
eases associated with aberrant NRF2 activity.
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